Sano has acquired technology from Texas A&M University for a novel first-in-class therapeutic for the treatment of serious Gram-positive infections. Mutacin 1140 analogs hold significant promise for the treatment of Gram-positive pathogens, and several have been identified for clinical development. A careful understanding of the structural elements that do not interfere with the antibiotic’s bioactivity or interfere with the antibiotic’s post-translational modifications was necessary. Therapeutic leads with potent activity against MRSA and S. pneumoniae that have improved pharmacokinetic properties and a demonstrated efficacy are being developed into a novel MRSA therapeutic and a novel treatment for a systemic bacterial infection.
What is Mutacin?
Mutacin is a first-in-class therapeutic for the treatment of Gram-positive infections. Due to its unique mechanism of action it is active against vancomycin and methicillin resistant Gram-positive pathogens.
How is it made?
Mutacin is isolated from our proprietary bacterial strains at our own facilities. We utilize industry-standard equipment and techniques to cultivate and harvest the bacteria before isolating the valuable mutacin from the culture.
Mutacin has been demonstrated superiority to vancomycin in a preclinical methicillin-resistant Staphylococcus aureus systemic infection model.
Fighting Antimicrobial Resistance
Drug-resistant bacterial infections are becoming an increasing threat with the decline of investment into novel antimicrobials. Mutacin is part of a resurgence in the development of the antimicrobial pipeline that will stave off the dangers of drug-resistant pathogens.